Aequus Pharmaceuticals (CVE:AQS) Hits New 1-Year Low – Should You Sell?

Aequus Pharmaceuticals Inc. (CVE:AQS)’s stock price reached a new 52-week low during trading on Wednesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 5000 shares changing hands. The stock had previously closed at C$0.01.

Aequus Pharmaceuticals Stock Performance

The company has a quick ratio of 0.46, a current ratio of 0.07 and a debt-to-equity ratio of 138.88. The stock has a fifty day simple moving average of C$0.01 and a 200 day simple moving average of C$0.02. The firm has a market capitalization of C$1.33 million, a P/E ratio of -1.00 and a beta of -0.02.

Aequus Pharmaceuticals (CVE:AQS) last posted its quarterly earnings results on Thursday, August 29th. The company reported C($0.01) EPS for the quarter. The business had revenue of C$0.16 million during the quarter. As a group, research analysts forecast that Aequus Pharmaceuticals Inc. will post -0.1 EPS for the current year.

About Aequus Pharmaceuticals

Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.